Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in relapsed/refractory classical Hodgkin lymphoma
NCT04486391Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Dec 2020
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in classical Hodgkin lymphoma (cHL), sponsored by BeiGene. Started Dec 2020; status: terminated.
02
Drugs
tislelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04486391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486391.